ATE106717T1 - Orale heilmittelform für dauerverabreichung. - Google Patents

Orale heilmittelform für dauerverabreichung.

Info

Publication number
ATE106717T1
ATE106717T1 AT90906689T AT90906689T ATE106717T1 AT E106717 T1 ATE106717 T1 AT E106717T1 AT 90906689 T AT90906689 T AT 90906689T AT 90906689 T AT90906689 T AT 90906689T AT E106717 T1 ATE106717 T1 AT E106717T1
Authority
AT
Austria
Prior art keywords
drug
particles
stomach
continuous administration
solution
Prior art date
Application number
AT90906689T
Other languages
English (en)
Inventor
John W Shell
Original Assignee
Depomed Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Systems Inc filed Critical Depomed Systems Inc
Application granted granted Critical
Publication of ATE106717T1 publication Critical patent/ATE106717T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90906689T 1989-04-11 1990-04-10 Orale heilmittelform für dauerverabreichung. ATE106717T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/336,440 US5007790A (en) 1989-04-11 1989-04-11 Sustained-release oral drug dosage form

Publications (1)

Publication Number Publication Date
ATE106717T1 true ATE106717T1 (de) 1994-06-15

Family

ID=23316106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90906689T ATE106717T1 (de) 1989-04-11 1990-04-10 Orale heilmittelform für dauerverabreichung.

Country Status (10)

Country Link
US (1) US5007790A (de)
EP (1) EP0467975B1 (de)
JP (1) JP2878837B2 (de)
KR (1) KR0167078B1 (de)
AT (1) ATE106717T1 (de)
AU (1) AU638012B2 (de)
CA (1) CA2014451C (de)
DE (1) DE69009755T2 (de)
FI (1) FI914765A0 (de)
WO (1) WO1990011757A1 (de)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484106A1 (de) * 1990-11-01 1992-05-06 Merck & Co. Inc. Geregelte Verabreichungszusammensetzungen
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
DE4140194C2 (de) * 1991-12-05 1998-02-19 Alfatec Pharma Gmbh Ein Dihydropyridinderivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
ES2092808T3 (es) * 1992-01-17 1996-12-01 Alfatec Pharma Gmbh Cuerpos solidos con contenido en principio activo con una estructura a base de macromoleculas hidrofilas y procedimiento para su produccion.
ATE173159T1 (de) * 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5614212A (en) * 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
JPH08507747A (ja) * 1992-12-30 1996-08-20 クローバー コンソリデイテッド，リミテッド 生物学的活性物質用の細包を保護し生体に適合する、再利用可能なマクロカプセル封入システム
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5919491A (en) * 1994-05-13 1999-07-06 Smithkline Beecham Corporation Method and composition for increasing calcium uptake
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
NZ311474A (en) 1995-06-09 1997-09-22 Euro Celtique Sa Formulations for providing prolonged local anesthesia
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
WO1997049391A1 (en) 1996-06-24 1997-12-31 Euro-Celtique, S.A. Methods for providing safe local anesthesia
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6248345B1 (en) 1997-07-02 2001-06-19 Euro-Celtique, S.A. Prolonged anesthesia in joints and body spaces
DE19734538C1 (de) * 1997-07-30 1998-12-24 Jenapharm Gmbh Bioadhäsive Tablette
PT1003476E (pt) * 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
EP1063973B1 (de) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Zweiphasiges kontrolliertes verabreichungssystem für hochlösliche arzneimittel und verwandtes verfahren
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
ES2253851T3 (es) 1998-08-07 2006-06-01 Curis, Inc. Composicion farmaceutica estable de proteinas hedgehog y uso de la misma.
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ES2304980T3 (es) * 1999-09-30 2008-11-01 Penwest Pharmaceuticals Co. Sistemas de matriz de liberacion sostenida para farmacos altamente solubles.
AU764453B2 (en) * 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
WO2003097018A1 (en) * 2002-02-04 2003-11-27 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
NZ527832A (en) * 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
AR040682A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20040106590A1 (en) * 2002-08-29 2004-06-03 Barry Eisenstein Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
AU2003299838A1 (en) * 2002-12-19 2004-07-14 Polymorfix, Inc. Ingestible formulations for transient, noninvasive reduction of gastric volume
MXPA05007381A (es) 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para el tratamiento de transtornos funcionales del intestino.
EP1592453A1 (de) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate aufbau von milnacipran für orale einnahme
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1677759A1 (de) * 2003-10-31 2006-07-12 Alza Corporation Zusammesetzungen und dosierformen für die verbeserte absorption von gabapentin und pregabalin
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
CN1988884B (zh) * 2004-06-10 2013-01-02 格拉特气体技术公司 控制释放基质的药物剂型组成
CA2569015A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
HRP20100682T4 (hr) * 2004-08-13 2014-08-01 Boehringer Ingelheim International Gmbh Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
US20060094760A1 (en) * 2004-11-04 2006-05-04 Fawzy Abdel A Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
FR2878159B1 (fr) * 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) * 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
CN101534808A (zh) 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
US8221792B2 (en) * 2005-07-07 2012-07-17 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
CA2620370A1 (en) * 2005-08-30 2007-03-22 Nicholas Piramal India Limited Extended release pharmaceutical composition of metformin and a process for producing it
EP1954257A4 (de) * 2005-10-14 2009-05-20 Lundbeck & Co As H Verfahren zur behandlung von erkrankungen des zentralen nervensystems mit einer niedrigdosierten kombination aus escitalopram und bupropion
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US9125803B2 (en) * 2005-12-30 2015-09-08 Shionogi Inc. Gastric release pulse system for drug delivery
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
CA2641665A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
JP5162134B2 (ja) * 2007-01-22 2013-03-13 愛媛県 機能性材料の製造方法、機能性材料、シート状構造体、及び衛生製品
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (de) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
EP2192892A2 (de) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsierende im magen gehaltene dosierformen
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
WO2009132461A1 (en) * 2008-04-28 2009-11-05 Electronic Dietary Foods Inc. Bezoar-forming units for weight control
US20090285865A1 (en) * 2008-05-14 2009-11-19 Shalaby Shalaby W Palatable, solid oral formulations for male chemical sterilization
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
JP2012500221A (ja) * 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
US20110268666A1 (en) * 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
BRPI1013856A2 (pt) 2009-04-20 2016-04-05 Elcelyx Therapeutics Inc terapias à base de ligantes de receptores quimiossensíveis
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
EP2427243A4 (de) 2009-05-05 2012-11-21 Vapogenix Inc Neue formulierungen flüchtiger anästhetika und anwendungsverfahren zur entzündungslinderung
WO2011072069A2 (en) * 2009-12-08 2011-06-16 Depomed, Inc. Gastric retentive pharmaceutical compositions for extended release of polypeptides
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2011146611A1 (en) * 2010-05-18 2011-11-24 Abon Pharmaceuticals, Llc Modified gastroretentive drug delivery system for amine drugs
CN103347517B (zh) 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201370099A1 (ru) 2010-10-19 2013-11-29 Элселикс Терапьютикс, Инк. Терапия на основе лигандов хемосенсорных рецепторов
JP6076913B2 (ja) 2010-12-07 2017-02-08 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013096744A1 (en) 2011-12-21 2013-06-27 Novira Therapeutics, Inc. Hepatitis b antiviral agents
KR20200137035A (ko) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
EP3378472A1 (de) 2012-08-09 2018-09-26 Dynamis Therapeutics, Inc. Megluminkombinationen
PT2941233T (pt) 2013-01-07 2020-11-13 Univ Pennsylvania Composições e métodos para tratar linfoma cutâneo de células t
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
RU2673737C2 (ru) 2013-07-02 2018-11-29 ЭКОПЛЭНЕТ ЭНВАЙРОНМЕНТАЛ, ЭлЭлСи Композиции летучих органических веществ, обладающие антимикробной активностью
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
WO2015080943A1 (en) 2013-11-26 2015-06-04 Yale University Novel cell-penetrating compositions and methods using same
EP3079692A4 (de) 2013-12-09 2017-10-18 Thomas Jefferson University Neuartiges verfahren zur behandlung einer neurodegenerativen krankheit bei einem säugetier mit derartigem bedarf
RU2565396C1 (ru) * 2014-04-01 2015-10-20 Александр Александрович Кролевец Способ получения нанокапсул аспирина в альгинате натрия
EP3128996B1 (de) 2014-04-07 2021-06-02 University of Rochester Neuartige 7-dehydrocholesterinderivate und verfahren damit
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2015191922A1 (en) 2014-06-11 2015-12-17 Massachusetts Institute Of Technology Enteric elastomers
EP3182979B1 (de) 2014-08-20 2023-12-06 Yale University Neuartige zusammensetzungen und verfahren zur behandlung oder prävention von lebererkrankungen oder -störungen und zur förderung von gewichtsverlust
KR101642193B1 (ko) * 2014-10-13 2016-07-25 씨제이헬스케어 주식회사 메트포르민 서방성 제제 및 그의 제조방법
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
KR20160105662A (ko) 2015-02-27 2016-09-07 대원제약주식회사 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
CA2983272C (en) 2015-05-01 2023-08-29 Massachusetts Institute Of Technology Triggerable shape memory induction devices
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
KR20250078598A (ko) 2015-05-19 2025-06-02 예일 유니버시티 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
WO2017003822A1 (en) 2015-06-30 2017-01-05 Galleon Pharmaceuticals, Inc. Novel breathing control modulating compounds, and methods of making and using same
HK1258050A1 (zh) 2015-10-23 2019-11-01 Lyndra Therapeutics, Inc. 用於治疗剂缓释的胃驻留系统及其使用方法
EP3368505B1 (de) 2015-10-28 2023-02-22 Yale University Chinolinamide und verfahren zur verwendung davon
WO2017087936A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
EP3386488B1 (de) 2015-12-08 2023-09-06 Lyndra Therapeutics, Inc. Geometrische konfigurationen für magenverweilsysteme
CN105418861B (zh) * 2015-12-10 2018-02-13 宁波大学 一种基于聚氨基酸分子交联水凝胶及其制备方法
WO2017123634A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
JP7418958B2 (ja) 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
EP3448369B1 (de) 2016-04-29 2025-06-25 The Regents of The University of Colorado, A Body Corporate Hemmung oder abbau von hdac11 zur behandlung von fettleibigkeit, hyperlipidämie, typ-ii-diabetes, metabolischem syndrom oder insulinresistenz, und zur förderung der gewichtsabnahme und/oder zur linderung oder verhinderung einer gewichtszunahme
AU2017268840B2 (en) 2016-05-27 2022-02-10 Nortiva Bio, Inc. Materials architecture for gastric residence systems
DK3484475T3 (da) 2016-07-18 2023-11-27 Pharmena S A 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
BR112019002355A2 (pt) 2016-08-05 2019-07-16 Yale University composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
EP3506983B1 (de) 2016-09-01 2021-08-25 Mebias Discovery, Inc. Substituierte harnstoff-derivate zur behandlung von schmerz
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
TWI794190B (zh) 2016-11-07 2023-03-01 加拿大商愛彼特生物製藥公司 含有取代的吡啶酮之三環化合物及其使用方法
US20180161279A1 (en) 2016-12-14 2018-06-14 Amgen Inc. Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
EP3571196B1 (de) 2017-01-19 2023-01-04 Temple University Of The Commonwealth System Of Higher Education Neuartige verbrückte bicycloalkyl-substituierte aminothizole und verfahren zu deren verwendung
AU2018238138A1 (en) 2017-03-21 2019-10-17 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JP7108018B2 (ja) 2017-04-17 2022-07-27 イエール ユニバーシティ 急性肺傷害を処置または予防する化合物、組成物および方法
US12023406B2 (en) 2017-06-09 2024-07-02 Lyndra Therapeutics, Inc. Gastric residence systems with release rate-modulating films
EP3659307A4 (de) 2017-07-28 2021-09-22 Yale University Antikrebsmittel und verfahren zur herstellung und verwendung davon
SG11202002060XA (en) 2017-09-08 2020-04-29 Univ Colorado Regents Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
US20200323895A1 (en) 2017-11-27 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
KR102678696B1 (ko) 2017-12-01 2024-06-27 울트라제닉스 파마수티컬 인코포레이티드 크레아틴 전구약물, 조성물과 이의 사용 방법
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
CA3089236A1 (en) 2018-01-24 2019-08-01 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
CA3101680A1 (en) 2018-05-25 2019-11-28 Temple University-Of The Commonwealth System Of Higher Education Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
AU2019279761A1 (en) 2018-05-29 2020-12-10 Cersci Therapeutics, Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
TWI869058B (zh) 2018-07-27 2025-01-01 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
CA3109798A1 (en) 2018-08-17 2020-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
AU2018445164B2 (en) 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
US12458601B2 (en) 2018-10-19 2025-11-04 Temple University-Of The Commonwealth System Of Higher Education Tamper-resistant drug dosage forms and methods of making and use thereof
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
CN113365636A (zh) 2019-01-30 2021-09-07 萨尼菲特治疗有限公司 用于增加组织灌注的磷酸肌醇化合物
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
WO2020210697A1 (en) 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
IL287617B2 (en) 2019-05-09 2024-11-01 Feinstein Institutes For Medical Research Hmgb1 antagonist
WO2020252407A1 (en) 2019-06-12 2020-12-17 The Wistar Institute Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (de) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol-phosphat-verbindungen zur verwendung in der behandlung, progressionshemmung oder verhinderung von kardiovaskulärer verkalkung
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
IL298853A (en) 2020-06-09 2023-02-01 Inozyme Pharma Inc Soluble enpp1 or enpp3 proteins and uses thereof
EP4216949A4 (de) 2020-09-28 2024-12-11 Yale University Selektive agonisten des 5-ht2a-rezeptors und verfahren zur verwendung
EP4477215A3 (de) 2020-12-08 2025-02-19 Ruminant Biotech Corp Limited Verbesserungen an vorrichtungen und verfahren zur abgabe von substanzen an tiere
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
EP4036097A1 (de) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6-substituierte derivatverbindungen
CA3263498A1 (en) 2022-07-29 2024-02-01 Vifor (International) Ltd. IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS INTENDED FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION AND PREVENTION OF ECTOPIC CALCIFICATION
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
US20260083759A1 (en) 2022-09-06 2026-03-26 Hadasit Medical Research Services And Development Ltd Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders
CN121729233A (zh) 2023-08-14 2026-03-24 纽瑞姆制药（1991）有限公司 Gal475组合物及其使用方法
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
CN117919237A (zh) * 2023-12-25 2024-04-26 盐城凯龙药业有限公司 一种西咪替丁及其合成方法
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025217096A1 (en) 2024-04-08 2025-10-16 University Of Rochester Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025217094A1 (en) 2024-04-08 2025-10-16 University Of Rochester Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217379A1 (en) 2024-04-10 2025-10-16 University Of Rochester Drug treatment for macular degeneration
WO2026050206A1 (en) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
US3435110A (en) * 1966-03-21 1969-03-25 Ethicon Inc Collagen fibril matrix pharmaceuticals
CH582002A5 (de) * 1972-06-09 1976-11-30 Purdue Research Foundation
US3888975A (en) * 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US4001388A (en) * 1973-06-14 1977-01-04 Alza Corporation Ophthalmological bioerodible drug dispensing formulation
US3901232A (en) * 1973-10-26 1975-08-26 Alza Corp Integrated device for administering beneficial drug at programmed rate
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4055178A (en) * 1976-03-10 1977-10-25 Harrigan Roy Major Drug delivery device for preventing contact of undissolved drug with the stomach lining
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
WO1980000007A1 (en) * 1978-06-02 1980-01-10 A Rockey Medical sleeve
DE3106449A1 (de) * 1981-02-20 1982-09-09 Röhm GmbH, 6100 Darmstadt "in magensaft loesliche oder quellbare ueberzugsmasse und ihre verwendung in einem verfahren zum ueberziehen von arzneiformen"
JPS5858146A (ja) * 1981-10-05 1983-04-06 Tanabe Seiyaku Co Ltd 速放性マイクロカプセル
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
US4758436A (en) * 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system

Also Published As

Publication number Publication date
US5007790A (en) 1991-04-16
FI914765A7 (fi) 1991-10-09
WO1990011757A1 (en) 1990-10-18
AU638012B2 (en) 1993-06-17
CA2014451C (en) 1996-08-06
JPH04507088A (ja) 1992-12-10
AU5523490A (en) 1990-11-05
DE69009755D1 (de) 1994-07-14
EP0467975A4 (en) 1992-03-11
FI914765A0 (fi) 1991-10-09
KR0167078B1 (ko) 1999-01-15
EP0467975A1 (de) 1992-01-29
EP0467975B1 (de) 1994-06-08
CA2014451A1 (en) 1990-10-11
DE69009755T2 (de) 1994-10-20
KR920700620A (ko) 1992-08-10
JP2878837B2 (ja) 1999-04-05

Similar Documents

Publication Publication Date Title
ATE106717T1 (de) Orale heilmittelform für dauerverabreichung.
ES2124303T3 (es) Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
AU781718B2 (en) Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2213836T3 (es) Formas galenicas orales retenidas en el estomago, para la liberacion controlada de medicamentos debilmente solubles y de sustancia insoluble.
DE69122751D1 (de) Arzneimittelzusammensetzung mit kontrollierter wirkstoffabgabe
DE69812690D1 (de) Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen
WO1997047285A1 (en) Gastric-retentive oral controlled drug delivery system with enhanced retention properties
DE60021604D1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
ES2162874T3 (es) Composicion farmaceutica para hacer llegar medicamentos hasta el colon.
PT96921B (pt) Dispositivo de libertacao intermitente
SE7704764L (sv) Framstellning av oral berarebas jemte derav framstellda doseringsenheter
Aslam et al. Techniques and polymers used to design Gastroretentive drug delivery systems–a review
US3784683A (en) Tablet preparation
Zope Janhavi et al. A Comprehensive Review on Gastro-Retentive Floating Drug Delivery Systems
Nagansurkar et al. An in-depth look into floating formulations, an innovative approach to drug delivery
Raza et al. Various formulation variables effecting floatation behaviour of single unit gastroretentive capsules of ofloxacin
Lodhi et al. FLOATING MICROSPHERES A NOVEL APPROACH IN FLOATING DRUG DELIVERY SYSTEM A REVIEW
Hussain et al. Formulation and evaluation of gastro retentive effervescent floating matrix tablets of Cephalexin
BASSLER DEVELOPMENT OF CONTROLLED GASTRIC RETENTION DRUG DELIVERY SYSTEMS AND A ROTARY VACUUM IMMERSION COATING DEVICE
Gangadharappa et al. APTI ijper
PHARMACEUTICS A Dissertation submitted to
Lalitha et al. FORMULATION AND EVALUATION OF AZITHROMYCIN MICROSPHERES
KR et al. Critical assessment pertaining to Gastric Floating Drug Delivery Systems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee